Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Complete your account application and verification in just 1 minute. The process is fully self-service and available on both RockFlow App and Web.

Once your account has been verified, you can deposit funds into your account using your preferred payment method.

Search for ENLV via RockFlow App or Web, enter the amount you want to invest, and tap Confirm to execute the trade.